3.2.4. Edoxaban

Edoxaban directly inhibits factor Xa. Maximal blood concentration of the drug is achieved 1– 2 h after the ingestion. About 40–59% of the drug is bound to plasma protein. Roughly 35% of the drug is excreted through the kidneys and the remainder through the liver. The drug halflife is 9–14 h. Therapeutic doses are 60 and 30 mg daily for patients with atrial fibrillation and VTE. The prophylactic dose for patients with total hip or knee replacement is 30 mg once daily. Edoxaban prolongs APTT and PT, but for a quantitative assessment of the drug level, an anti-Xa test calibrated to edoxaban must be utilized [36, 37].
